Advertisement

International Journal of Hematology

, Volume 106, Issue 6, pp 732–747 | Cite as

JSH guideline for tumors of hematopoietic and lymphoid tissues—leukemia: 3. Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL)

  • Jin TakeuchiEmail author
  • Shigeru Kusumoto
  • Hideki Akiyama
  • Yoshinobu Kanda
  • Koji Izutsu
Guide Line

Overview

Acute leukemia and malignant lymphoma were once believed to be malignancies originating in the bone marrow and lymph nodes, respectively. Patients with lymphoblasts in the bone marrow were considered to have acute lymphoblastic leukemia (ALL), and patients without bone marrow involvement were considered to have lymphoblastic leukemia (LBL).

In the 2008 WHO classification, lymphoid malignancies were broadly classified into B cell malignancies and T-cell/natural killer (NK) cell malignancies and subclassified by the approximate stage of differentiation of normal lymphoid cells they resemble (Table  1) [1]. Essentially, ALL/LBL is classified by whether it originates in precursor B-cells (called B-cell lymphoblastic leukemia/lymphoma) or precursor T-cells (called T-cell lymphoblastic leukemia/lymphoma), and B-cell lymphoblastic leukemia/lymphoma is further classified as “not otherwise specified” or “with recurrent genetic abnormalities” [1]. The table below shows these...

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Jin Takeuchi
    • 1
    Email author
  • Shigeru Kusumoto
    • 2
  • Hideki Akiyama
    • 3
  • Yoshinobu Kanda
    • 4
  • Koji Izutsu
    • 5
  1. 1.Hematology ClinicMeirikai Chuo General HospitalTokyoJapan
  2. 2.Department of Hematology and OncologyNagoya City University Graduate School of Medical SciencesNagoyaJapan
  3. 3.Hematology DivisionNitobe Memorial Nakano General HospitalTokyoJapan
  4. 4.Division of Hematology, Department of MedicineJichi Medical UniversityShimotsukeJapan
  5. 5.Department of HematologyNational Cancer Center HospitalTokyoJapan

Personalised recommendations